Sarcomas More Common in Children

[1]  Helen X. Chen,et al.  Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group , 2015, Pediatric blood & cancer.

[2]  G. Demetri,et al.  Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy , 2014, BMC Cancer.

[3]  J. Healey,et al.  Ewing sarcoma in adults treated with modern radiotherapy techniques. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  Jun S. Wei,et al.  The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation , 2014, PLoS genetics.

[5]  M. Beckerle,et al.  Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor Growth , 2014, Clinical Cancer Research.

[6]  G. Getz,et al.  Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. , 2014, Cancer discovery.

[7]  W. Shi,et al.  Adult rhabdomyosarcoma survival improved with treatment on multimodality protocols. , 2013, International journal of radiation oncology, biology, physics.

[8]  C. Keller,et al.  18F‐FDG microPET imaging detects early transient response to an IGF1R inhibitor in genetically engineered rhabdomyosarcoma models , 2012, Pediatric blood & cancer.

[9]  A. Llombart‐Bosch,et al.  Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma. , 2012, Human pathology.

[10]  J. Desai,et al.  Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Arul M Chinnaiyan,et al.  PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. , 2012, Cancer research.

[12]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[13]  O. Delattre,et al.  A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion , 2012, Nature Genetics.

[14]  C. Antonescu,et al.  High prevalence of CIC fusion with double‐homeobox (DUX4) transcription factors in EWSR1‐negative undifferentiated small blue round cell sarcomas , 2012, Genes, chromosomes & cancer.

[15]  M. Zielenska,et al.  The CIC-DUX4 fusion transcript is present in a subgroup of pediatric primitive round cell sarcomas. , 2012, Human pathology.

[16]  Helen X. Chen,et al.  Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  U. Dirksen,et al.  Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Reinke,et al.  R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Neuhaus,et al.  Clinical features and outcomes in patients with extraskeletal ewing sarcoma , 2011, Cancer.

[20]  Qing-Rong Chen,et al.  Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. , 2011, Journal of the National Cancer Institute.

[21]  James R. Anderson,et al.  Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's O , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Yingye Zheng,et al.  Genomic instability and copy‐number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas , 2011, Molecular oncology.

[23]  L. Helman,et al.  Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-xL , 2010, Oncogene.

[24]  C. Antonescu,et al.  EWSR1‐POU5F1 fusion in soft tissue myoepithelial tumors. A molecular analysis of sixty‐six cases, including soft tissue, bone, and visceral lesions, showing common involvement of the EWSR1 gene , 2010, Genes, chromosomes & cancer.

[25]  Daniel G. Miller,et al.  A Unifying Genetic Model for Facioscapulohumeral Muscular Dystrophy , 2010, Science.

[26]  G. L. de la Roza,et al.  Newly described translocation (18;19)(q23;q13.2) in abdominal wall soft-tissue tumor resembling Ewing sarcoma/primitive neuroectodermal tumor. , 2010, Cancer genetics and cytogenetics.

[27]  U. Dirksen,et al.  Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Zell,et al.  Analysis of prognostic factors in Ewing sarcoma using a population‐based cancer registry , 2010, Cancer.

[29]  J. Neuhaus,et al.  Ethnic and racial differences in patients with Ewing sarcoma , 2010, Cancer.

[30]  S. Schuetze,et al.  Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. , 2010, The Lancet. Oncology.

[31]  E. de Álava,et al.  Desmoplastic nested spindle cell tumor of the liver in an adult. , 2010, Annals of diagnostic pathology.

[32]  S. Wolden,et al.  Sarcomas across the age spectrum. , 2010, Seminars in radiation oncology.

[33]  A. Tolcher,et al.  Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  M. Shago,et al.  Detailed cytogenetic and array analysis of pediatric primitive sarcomas reveals a recurrent CIC-DUX4 fusion gene event. , 2009, Cancer genetics and cytogenetics.

[35]  A. Rosato,et al.  Undifferentiated sarcoma: does it exist? A clinicopathologic study of 7 pediatric cases and review of literature. , 2009, Human pathology.

[36]  F. Pedeutour,et al.  Fusion of EWSR1 with the DUX4 facioscapulohumeral muscular dystrophy region resulting from t(4;22)(q35;q12) in a case of embryonal rhabdomyosarcoma. , 2009, Cancer genetics and cytogenetics.

[37]  James R. Anderson,et al.  Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Paul A Meyers,et al.  Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  H. Makhlouf,et al.  Calcifying Nested Stromal-epithelial Tumors of the Liver: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 9 Cases With a Long-term Follow-up , 2009, The American journal of surgical pathology.

[40]  A. Hayes-Jordan,et al.  Rhabdomyosarcoma in children , 2009, Current opinion in pediatrics.

[41]  P. Leavey,et al.  Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  J. Crowley,et al.  A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  S. de Jong,et al.  The insulin‐like growth factor system and sarcomas , 2009, The Journal of pathology.

[44]  P. Sorensen,et al.  Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. , 2009, The American journal of pathology.

[45]  Xia Han,et al.  The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. , 2009, Cancer research.

[46]  L. Helman,et al.  Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. , 2008, Cancer research.

[47]  W. Winkelmann,et al.  Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  D. West,et al.  Randomized comparison of every-two-week v. every-three-week chemotherapy in Ewing sarcoma family tumors (ESFT) , 2008 .

[49]  D. Rakheja,et al.  Translocation (4;19)(q35;q13.1)–Associated Primitive round Cell Sarcoma: Report of a Case and Review of the Literature , 2008, Pediatric and Developmental Pathology.

[50]  D. Hawkins,et al.  Two boys with fragile x syndrome and hepatic tumors. , 2008, Journal of pediatric hematology/oncology.

[51]  U. Surti,et al.  EWSR1‐CREB1 is the predominant gene fusion in angiomatoid fibrous histiocytoma , 2007, Genes, chromosomes & cancer.

[52]  Soma Das,et al.  Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  J. Codina,et al.  Molecular biology of rhabdomyosarcoma , 2007 .

[54]  P. Thall,et al.  Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  K. S. Hall,et al.  Non-metastatic Ewing's family tumors: High-dose chemotherapy with stem cell rescue in poor responder patients. Preliminary results of the Italian/Scandinavian ISG/SSG III protocol , 2007 .

[56]  L. Helman,et al.  Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism , 2007, Oncogene.

[57]  S. Spunt,et al.  Distinguishing Undifferentiated Embryonal Sarcoma of the Liver from Biliary Tract Rhabdomyosarcoma: A Children's Oncology Group Study , 2007, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[58]  P. Houghton,et al.  Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  M Beth McCarville,et al.  Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma , 2007, Pediatric blood & cancer.

[60]  B. Geoerger,et al.  Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  A. McTiernan,et al.  Improving Outcomes After Relapse in Ewing's Sarcoma: Analysis of 114 Patients From a Single Institution , 2006, Sarcoma.

[62]  J. Ewing.  The Classic: Diffuse endothelioma of bone. Proceedings of the New York Pathological Society. 1921;12:17. , 2006, Clinical orthopaedics and related research.

[63]  P. Terrier,et al.  Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  J. Boos,et al.  Phase II study of gemcitabine in children with solid tumors of mesenchymal and embryonic origin , 2006, Anti-cancer drugs.

[65]  James R. Anderson,et al.  Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  H. Aburatani,et al.  Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation. , 2006, Human molecular genetics.

[67]  H. Kovar,et al.  Ewing's sarcoma family of tumors: current management. , 2006, The oncologist.

[68]  M. Carli,et al.  Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma , 2006, Cancer.

[69]  M. Ladanyi,et al.  Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  K. Anderson,et al.  Desmoplastic Nested Spindle Cell Tumor of Liver: Report of Four Cases of a Proposed New Entity , 2005, The American journal of surgical pathology.

[71]  W. Meyer,et al.  Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  A. McTiernan,et al.  Single center experience of a new intensive induction therapy for ewing's family of tumors: feasibility, toxicity, and stem cell mobilization properties. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  S. Donaldson,et al.  Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. , 2003, The New England journal of medicine.

[74]  Sung-Eun Jung,et al.  Undifferentiated (embryonal) sarcoma of the liver: combination treatment by surgery and chemotherapy. , 2002, Journal of pediatric surgery.

[75]  W. Gerald,et al.  Irinotecan for Pediatric Solid Tumors: The Memorial Sloan-Kettering Experience , 2002, Journal of pediatric hematology/oncology.

[76]  M. Bernstein,et al.  Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  James R. Anderson,et al.  Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  W. Winkelmann,et al.  Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  P. Meyers,et al.  How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  J. Meza,et al.  Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  C. Croce,et al.  Exon structure and promoter identification of STIM1 (alias GOK), a human gene causing growth arrest of the human tumor cell lines G401 and RD , 1999, Cytogenetic and Genome Research.

[82]  M. Bernstein,et al.  Topotecan in Pediatric Patients With Recurrent and Progressive Solid Tumors: A Pediatric Oncology Group Phase II Study , 1998, Journal of pediatric hematology/oncology.

[83]  D. Leroith,et al.  Expression of a kinase‐deficient IGF‐I‐R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF‐I‐R , 1998, International Journal of Cancer.

[84]  W. Gerald,et al.  EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  C. Stewart,et al.  Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  P. Adamson,et al.  Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[87]  A. Feinberg,et al.  A 2.5-Mb transcript map of a tumor-suppressing subchromosomal transferable fragment from 11p15.5, and isolation and sequence analysis of three novel genes. , 1997, Genomics.

[88]  C. Croce,et al.  GOK: a gene at 11p15 involved in rhabdomyosarcoma and rhabdoid tumor development. , 1997, Cancer research.

[89]  J. Finklestein,et al.  t(4;19)(q35;q13.1): a recurrent change in primitive mesenchymal tumors? , 1995, Cancer genetics and cytogenetics.

[90]  H. Werner,et al.  The Role of the Insulin‐like Growth Factor‐I Receptor in Cancer , 1995, Annals of the New York Academy of Sciences.

[91]  E. Gehan,et al.  The Third Intergroup Rhabdomyosarcoma Study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  Chuan Yi Tang,et al.  A 2.|E|-Bit Distributed Algorithm for the Directed Euler Trail Problem , 1993, Inf. Process. Lett..

[93]  E. Gehan,et al.  The intergroup rhabdomyosarcoma study‐II , 1993, Cancer.

[94]  L. Helman,et al.  IGF-II in the pathogenesis of rhabdomyosarcoma: a prototype of IGFs involvement in human tumorigenesis. , 1993, Advances in Experimental Medicine and Biology.

[95]  I. Lewis,et al.  12q13 abnormality in rhabdomyosarcoma. A nonrandom occurrence? , 1992, Cancer genetics and cytogenetics.

[96]  J. Biegel,et al.  Chromosomal Translocation t(1;13)(p36;q14) in a Case of Rhabdomyosarcoma , 1991, Genes, chromosomes & cancer.

[97]  E. Gehan,et al.  Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  E. Gehan,et al.  Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  E. Gehan,et al.  The intergroup rhabdomyosarcoma study‐I. A final report , 1988, Cancer.

[100]  H. Shimada,et al.  Histopathology of childhood sarcomas, Intergroup Rhabdomyosarcoma Studies I and II: clinicopathologic correlation. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  P. Houghton,et al.  A specific chromosomal abnormality in rhabdomyosarcoma. , 1987, Cytogenetics and cell genetics.

[102]  M. Beltangady,et al.  Infants younger than 1 year of age with rhabdomyosarcoma , 1986, Cancer.

[103]  M. Tattersall,et al.  Extraskeletal Ewing's sarcoma: a clinical, morphological and ultrastructural analysis of five cases with a review of the literature. , 1986, European journal of cancer & clinical oncology.

[104]  C. Turc‐Carel,et al.  Consistent chromosomal translocation in alveolar rhabdomyosarcoma. , 1986, Cancer genetics and cytogenetics.

[105]  G. Rosen,et al.  Mesenchymal chondrosarcoma a clinicopathologic analysis of 35 patients with emphasis on treatment , 1983, Cancer.

[106]  H. Maurer.  The Intergroup Rhabdomyosarcoma Study II: objectives and study design. , 1980, Journal of pediatric surgery.

[107]  K. Ishak,et al.  Undifferentiated (embryonal) sarcoma of the liver. Report of 31 cases , 1978, Cancer.

[108]  L. Norton,et al.  Tumor size, sensitivity to therapy, and design of treatment schedules. , 1977, Cancer treatment reports.

[109]  L. Norton,et al.  Predicting the course of Gompertzian growth , 1976, Nature.

[110]  Oldham Rk,et al.  Treatment of Ewing's sarcoma with adriamycin (NSC-123127). , 1972 .

[111]  J. Ewing.  Diffuse endothelioma of bone , 1972 .

[112]  H. G. Taylor,et al.  Prognosis in childhood rhabdomyosarcoma , 1970, Cancer.

[113]  Sutow Ww,et al.  Successful chemotherapy for childhood rhabdomyosarcoma. , 1970 .

[114]  M. Haggard,et al.  CYCLOPHOSPHAMIDE (NSC-26271)-1 IN UNCOMMON MALIGNANT NEOPLASMS IN CHILDREN. , 1964, Cancer chemotherapy reports.

[115]  D. Dahlin,et al.  Mesenchymal chondrosarcoma. Further observations on a new entity , 1962, Cancer.